Company profile: Semma Therapeutics
1.1 - Company Overview
Company description
- Provider of transformative therapies for Type 1 diabetes, leveraging an exclusively licensed breakthrough method from Professor Douglas Melton's lab to generate billions of functional, insulin-producing beta cells in the laboratory.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Semma Therapeutics
Poxel
HQ: France
Website
- Description: Provider of biopharmaceutical products for metabolic diseases, focusing on type 2 diabetes and NASH. Portfolio includes TWYMEEG (Imeglimin), approved in Japan for type 2 diabetes, targeting mitochondrial dysfunction; PXL065, a deuterium-stabilized R-pioglitazone for NASH with Phase 2 primary endpoint met; and PXL770, a direct AMPK activator for rare diseases including NASH and ALD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Poxel company profile →
Home Diagnostics
HQ: United States
Website
- Description: Provider of blood glucose monitoring systems and disposable supplies for diabetics, developed, manufactured and marketed by Home Diagnostics, offering performance and features comparable to or better than competitors' products, in most cases at a substantially lower price.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Home Diagnostics company profile →
Adocia
HQ: France
Website
- Description: Provider of biotechnology therapies specializing in tissue regeneration and diabetes treatments, developing medicines with already-approved therapeutic proteins. Offerings include BioChaperone Lispro ultra-rapid insulin, BioChaperone Combo glargine+lispro, AdoShell Islets hydrogel implant, M1Pram and BioChaperone LisPram co-formulations, and AdOral Sema oral semaglutide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adocia company profile →
Ypsomed
HQ: Switzerland
Website
- Description: Provider of injection and infusion systems for self-medication, partnering with pharmaceutical and biotechnology companies for injection pens and autoinjectors. Delivers mylife Diabetescare solutions including infusion systems, blood glucose monitoring and therapy management, the mylife YpsoPump insulin pump, YpsoMate autoinjector, and mylife Loop automated insulin dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ypsomed company profile →
Medesis Pharma
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical development leveraging AONYS, a buccal micro-emulsion platform enabling delivery of water-soluble actives across the blood-brain barrier, to develop orally administered candidates addressing unmet needs, including Nanolithium for Alzheimer's, NanoManganese for radiotherapy, NU01/NU02 for plutonium/cesium decorporation, and P42 for Huntington's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medesis Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Semma Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Semma Therapeutics
2.2 - Growth funds investing in similar companies to Semma Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Semma Therapeutics
4.2 - Public trading comparable groups for Semma Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →